Lemtrada is a medicine that is used to treat adults with relapsing-remitting multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves as well as the nerves themselves. ‘Relapsing-remitting’ means that the patient has attacks (relapses) between periods with few or no symptoms (remissions).
Lemtrada is used for patients with:
- disease that is highly active, even though they have been treated with a disease-modifying therapy;
- rapidly worsening, severe disease, who have had 2 or more relapses in one year and whose brain scans show certain brain lesions.
Lemtrada contains the active substance alemtuzumab.
Lemtrada : EPAR - Medicine overview (PDF/131.15 KB)
First published: 25/09/2013
Last updated: 29/01/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
|Date of issue of marketing authorisation valid throughout the European Union||
16/01/2020 Lemtrada - EMEA/H/C/003718 - A20/0028
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.